 Sydney, AUSTRALIA, Dec. 10, 2020 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to report encouraging first Overall Survival OS follow up data from its ongoing Phase IIb AIPAC study evaluating Immuteps lead product candidate eftilagimod alpha in combination with paclitaxel chemotherapy efti group in comparison to a combination of placebo and paclitaxel chemotherapy comparator group in patients with HER2-negativeHR positive metastatic breast cancer HR MBC. These data were selected to be presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, which is being held virtually this week from Texas, USA. 